Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.53 |
| ▸ | HTR1A | P08908 | 3/20 | 0.49 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | HTR2B | P41595 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL797398 | 0.98 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL9597404 | 0.89 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL23830859 | 0.85 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4125994 | 0.84 | HTR2C (0.59) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL17643355 | 0.84 | GRIN1 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4700578 | 0.84 | HTR2C (0.59) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL2114839 | 0.84 | GRIN1 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2114840 | 0.84 | GRIN1 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3380245 | 0.84 | HTR2C (0.59) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL17643108 | 0.84 | GRIN1 (0.44) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183255-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. LUNDBECK A/S (DK) | 2023-06-15 | — | — | US | claimed |
| US-20250326713-A1 | INHIBITORS OF MsbA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4525852-A1 | INHIBITORS OF MSBA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20240400578-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2024-12-05 | — | — | US | disclosed |
| US-11981681-B2 | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2024-05-14 | — | — | US | disclosed |
| EP-3724194-B1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2023-12-27 | — | — | EP | disclosed |
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-12-12 | — | — | US | disclosed |
| WO-2023224893-A1 | INHIBITORS OF MSBA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-111712502-B | Substituted azetidine dihydro-thienopyrimidines and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| EP-2389382-A1 | Amino-heterocyclic compounds used as pde9 inhibitors | Pfizer Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| US-8041687-B2 | Dynamic generation of XML Schema for backend driven data validation | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010084438-A1 | AMINO-HETEROCYCLIC COMPOUNDS USED AS PDE9 INHIBITORS | PFIZER INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010084438-A1 | AMINO-HETEROCYCLIC COMPOUNDS USED AS PDE9 INHIBITORS | PFIZER INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2003007939-A1 | AZETIDINE DERIVATIVES AND THEIR USE AS CCR3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2003-01-30 | — | — | WO | disclosed |
| US-4031221-A | ANALGESICS, TRANQUILIZERS, INDOLE COMPOUNDS | AMERICAN HOECHST CORPORATION (US) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | GABRA5, GABRA2, GABRB2 | SLC6A2 1136/4885SLC6A4 729/4885SLC6A3 710/4885 |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PDE9A, PDE2A, PDE10A | SLC6A2 411/4885SLC6A4 640/4885SLC6A3 122/4885 |
| US-20230183255-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | PDE9A, PDE5A, PDE3A | SLC6A2 3880/4885SLC6A4 3337/4885SLC6A3 2912/4885 |
| US-20250326713-A1 | INHIBITORS OF MsbA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MSRB3, ARSA, ABCG2 | SLC6A2 2932/4885SLC6A4 2421/4885SLC6A3 2474/4885 |
| US-11981681-B2 | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | PDE2A, PDE3A, PDE3B | SLC6A2 710/4885SLC6A4 1239/4885SLC6A3 484/4885 |
| US-20240400578-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE2A, PDE3A, PDE3B | SLC6A2 710/4885SLC6A4 1239/4885SLC6A3 484/4885 |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | SLC6A2 4715/4885SLC6A4 4745/4885SLC6A3 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.